secwatch / observer
8-K filed August 3, 2023, 7:59 PM ET ticker RMD CIK 0000943819
earnings confidence high sentiment positive materiality 0.75

ResMed Q4 FY2023 revenue up 23% to $1.12B; EPS $1.56 GAAP, dividend raised 9% to $0.48

RESMED INC

2023-FY EPS reported $6.09 revenue$4,222,993,000

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

RESMED INC reported fiscal year ended June 30, 2023 results: revenue $4,223.0, net income $897.6, EPS $6.09.

Period
fiscal year ended June 30, 2023
Revenue
$4,223.0
Net income
$897.6
EPS
$6.09
Result
reported results
Exact text from the filing
per share $ 1.56 $ 1.33 17 Non-GAAP diluted earnings per share (B) $ 1.60 $ 1.49 7 Twelve Months Ended June 30, 2023 June 30, 2022 % Change Constant Currency (A) Revenue $ 4,223.0 $ 3,578.1 18 % 21 % Gross margin 55.8 % 56.6 % (1 ) Non-GAAP gross margin (B) 56.5 % 57.7 % (2 ) Selling, general, and administrative expenses 874.0 737.5 19 22 Research and
View on SEC.gov
Earnings Releases SEC 8-K Item 2.02 confidence 0.9

RESMED INC reported the quarter ended June 30, 2023 results: revenue $1,122.1, net income $229.7, EPS $1.56.

Period
the quarter ended June 30, 2023
Revenue
$1,122.1
Net income
$229.7
EPS
$1.56
Result
reported results
Exact text from the filing
Results and Operating Metrics Unaudited; $ in millions, except for per share amounts Three Months Ended June 30, 2023 June 30, 2022 % Change Constant Currency (A) Revenue $ 1,122.1 $ 914.7 23 % 23 % Gross margin 55.0 % 57.1 % (4 ) Non-GAAP gross margin (B) 55.8 % 57.8 % (4 ) Selling, general, and administrative expenses 240.7 193.0 25 26 Research and
View on SEC.gov

Browse all earnings releases →

RESMED INC filing history →

Source: SEC EDGAR
accession 0001193125-23-202850
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.